Manufacturing and Management of CAR T-Cell Therapy in “COVID-19’s Time”: Central Versus Point of Care Proposals

The COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has generated a significant repercussion on the administration of adoptive cell therapies, including chimeric antigen receptor (CAR) T-cells. The closing of borders, the reduction of people transit and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortiz de Landazuri, Iñaki, Egri, Natalia, Muñoz-Sánchez, Guillermo, Ortiz-Maldonado, Valentín, Bolaño, Victor, Guijarro, Carla, Pascal, Mariona, Juan, Manel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593817/
https://www.ncbi.nlm.nih.gov/pubmed/33178200
http://dx.doi.org/10.3389/fimmu.2020.573179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593817/
https://www.ncbi.nlm.nih.gov/pubmed/33178200
http://dx.doi.org/10.3389/fimmu.2020.573179

Ejemplares similares